SCHEMBL3668239

SCHEMBL3668239

O=C(NCCN1CCOCC1)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 7/20 0.60
PRKACA P17612 5/20 0.60
CDK2 P24941 5/20 0.60
ROCK2 O75116 5/20 0.60
ROCK1 Q13464 5/20 0.60
DYRK1A Q13627 5/20 0.60
GSK3B P49841 4/20 0.60
CLK4 Q9HAZ1 4/20 0.60
MKNK2 Q9HBH9 4/20 0.60
AURKA O14965 4/20 0.60
CDK1 P06493 4/20 0.60
AKT1 P31749 4/20 0.60
GSK3A P49840 4/20 0.60
RPS6KA3 P51812 4/20 0.60
CDK5 Q00535 4/20 0.60
PRKCD Q05655 4/20 0.60
PRKAA1 Q13131 4/20 0.60
CDC42BPA Q5VT25 4/20 0.60
AURKB Q96GD4 4/20 0.60
PRKD2 Q9BZL6 4/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4284847 0.84 CDC7 (0.78) CDC7PRKACACDK2ROCK2ROCK1
SCHEMBL3666406 0.84 ROCK2 (0.71) CDC7PRKACACDK2ROCK2ROCK1
SCHEMBL3669280 0.82 CDC7 (0.62) CDC7PRKACACDK2ROCK2ROCK1
SCHEMBL3667233 0.81 ROCK2 (0.66) CDC7PRKACACDK2ROCK2ROCK1
SCHEMBL3672888 0.80 CDC7 (0.64) CDC7PRKACACDK2ROCK2ROCK1
SCHEMBL3671481 0.80 ROCK2 (0.71) CDC7PRKACACDK2ROCK2ROCK1
SCHEMBL3637481 0.80 CDC7 (0.60) CDC7PRKACACDK2ROCK2ROCK1
SCHEMBL3638017 0.80 CDC7 (0.60) CDC7PRKACACDK2ROCK2ROCK1
SCHEMBL3673958 0.80 CDC7 (0.66) CDC7PRKACACDK2ROCK2ROCK1
SCHEMBL3667213 0.80 GSK3B (0.79) CDC7PRKACACDK2ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US claimed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP claimed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US claimed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO claimed
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
EP-2167491-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS Abbott Laboratories (US) 2010-03-31 EP disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed
WO-2008154241-A1 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885PRKACA 178/4885CDK2 65/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 CDC7 8/4885PRKACA 178/4885CDK2 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.